In an editorial titled “Welcome to Montreal, Moderna. But…” Philippe Mercure says pharmaceutical companies have refused to share their expertise to get more vaccines made around the world. The reality, however, is quite different, as many technology transfers are taking place for vaccines as well as for treatments against COVID-19.

Across the top five COVID-19 vaccine manufacturers, more than 300 partnerships are driving the production of billions of vaccine doses. At Pfizer and BioNTech, our supply chain and manufacturing network now spans four continents and includes more than 20 facilities.

Our voluntary license agreements have been established with partners who have an excellent track record of producing quality vaccines and who have the capacity for large-scale production. This has enabled us to produce three billion doses in 2021 and to anticipate the production of four billion doses in 2022. All this while respecting the highest quality standards.

Additionally, early in the pandemic, to ensure equitable and affordable access to COVID-19 vaccines worldwide, we introduced tiered pricing:

In addition, we signed a voluntary license agreement with the Medicines Patent Pool (MPP) to share intellectual property related to our oral treatment for COVID-19 (Paxlovid) in order to allow generic drug manufacturers licensed to produce and distribute generic versions of the treatment. Last March, the MPP granted sublicenses to 36 manufacturers from 13 countries. These voluntary licenses will help improve access to Paxlovid in 95 low- and middle-income countries, representing 53% of the world’s population.

Ending the pandemic and vaccinating the entire planet is a major challenge. Real solutions to improving access to vaccines include strengthening and maintaining healthcare infrastructure to administer the vaccine, supporting frontline workers to administer the vaccine, and campaigning against vaccine hesitancy. vaccine to increase vaccine acceptance. In the meantime, we will continue to explore and pursue opportunities to integrate new partners into our supply chain.

https://www.lapresse.ca/debats/opinions/2022-05-12/vaccins-contre-la-covid-19/les-transferts-de-technologies-existent-deja.php

LEAVE A REPLY

Please enter your comment!
Please enter your name here